Efficacy and Safety of Timolol for TKI Induced Paronychia

Launched by QUEEN MARY HOSPITAL, HONG KONG · Nov 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called timolol, used in combination with another medication, betamethasone, to treat paronychia. Paronychia is an infection or inflammation that affects the skin around the fingernails and toenails, which can occur as a side effect of certain cancer treatments known as EGFR-TKIs. The trial will involve adults aged 18 and older who are currently experiencing paronychia after taking EGFR-TKIs like gefitinib or erlotinib.

Participants in the study will be randomly assigned to either receive the combination of timolol and betamethasone or just betamethasone alone, both applied twice daily for one month. If their condition doesn’t fully improve after four weeks, the treatment may continue for up to three months. This trial is actively recruiting participants and aims to help improve treatment options for those affected by this uncomfortable condition. If you or someone you know fits the eligibility criteria and is interested in participating, it could be a valuable opportunity to contribute to medical research while potentially receiving effective treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged 18 years or above, either males or females.
• • 2. Received EGFR-TKI, namely gefitinib, erlotinib, afatinib, osimertinib, amivantamab, dacomitinib and mobocertinib.
• • 3. Paronychia (fingernails, toenails, or both) as an adverse event from EGFR-TKI use.
• • 4. Written informed consent obtained from patient.
• Exclusion Criteria:
• • 1. Age below18.
• • 2. Patients who are allergic to, or contraindicated to topical timolol use.
• • 3. Pregnant women or nursing mother.
• • 4. Non-consenting patients.